Nitric Oxide

also known as iNO · Inhaled NO · NONS · Enovid · gNO · Inhaled nitric oxide · inhaled nitric oxide, iNO, iNOMax · INO max · +5 more

Other / unclassified targets CFTR via activation

Developed for: pulmonary hypertension · COVID-19 · acute kidney injury · congenital heart disease · pulmonary arterial hypertension · sickle cell disease · viral pneumonia · lung disorder
+63 more
· bronchopulmonary dysplasia · cardiac arrest · chronic obstructive pulmonary disease · coronary artery disorder · cystic fibrosis · infectious disease with sepsis · persistent fetal circulation syndrome · pneumonia · pulmonary fibrosis · ulcer of lower limbs · acute bronchiolitis · acute respiratory distress syndrome · aspiration pneumonia · cardiovascular disorder · ischemic disease · liver disorder · newborn respiratory distress syndrome · pulmonary embolism · respiratory distress syndrome in premature infants · respiratory failure · severe acute respiratory syndrome · tinea pedis · acidosis disorder · acute chest syndrome · acute respiratory failure · anemia, nonspherocytic hemolytic · bacterial pneumonia · bronchiolitis · cancer · cerebral malaria · cerebral palsy · chronic rhinosinusitis · congenital diaphragmatic hernia · congenital heart malformation · decubitus ulcer · erectile dysfunction · heart failure · high altitude pulmonary edema · idiopathic pulmonary fibrosis · intracranial vasospasm · malaria · methicillin-resistant staphylococcus aureus infectious disease · mycobacterial infectious disease · myocardial ischemia · oral candidiasis · Orthocoronavirinae infectious disease · platelet disorder, undefined · polycythemia due to hypoxia · pulmonary hypertension owing to lung disease and/or hypoxia · pulmonary non-tuberculous mycobacterial infection · respiratory tract infectious disorder · ST-elevation myocardial infarction · tinea infection · traumatic brain injury · ulcer disease · vascular disorder · acute myocardial infarction · cardiogenic shock · congestive heart failure · myocardial infarction · pediatric acute respiratory distress syndrome · plantar wart · transposition of the great arteries
Investigated by: Mallinckrodt · Massachusetts General Hospital · Beyond Air Inc. · National Heart, Lung, and Blood Institute (NHLBI) · Nitric BioTherapeutics, Inc · Bellerophon Pulse Technologies
+131 more
· Xijing Hospital · Bellerophon · Tomsk National Research Medical Center of the Russian Academy of Sciences · University of Alberta · Geno LLC · Marrazzo, Francesco, M.D., Massachusetts General Hospital · NICHD Neonatal Research Network · National Center for Research Resources (NCRR) · Sanotize Research and Development corp. · Spina, Stefano, M.D., Massachusetts General Hospital · University of Alabama at Birmingham · University of Colorado, Denver · Wake Forest University Health Sciences · Zadek, Francesco, M.D., Massachusetts General Hospital · Canadian Institutes of Health Research (CIHR) · Children's Hospital Medical Center, Cincinnati · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · National Institutes of Health Clinical Center (CC) · Shanghai Zhongshan Hospital · Soroka University Medical Center · Tufts Medical Center · University Health Network, Toronto · ARAMU Association · Actelion · Air Liquide SA · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Andrei Bautin, The Almazov National Medical Research Centre, St. Petersburg, Russian Federation · Asan Medical Center · Assistance Publique - Hôpitaux de Paris · Beijing Anzhen Hospital · Bellerophon Therapeutics · Bonventre, Joseph V., M.D., Brigham Women Hospital · Boston Children's Hospital · Cameron Dezfulian · Canadian Lung Association · Children's Hospital of Fudan University · Children's Hospital of Hebei Province · Chungnam National University Hospital · Clinical & Translational Science Institute of Southeast Wisconsin · Cystic Fibrosis Foundation · Dr. Denis O'Donnell · Duke University · Ellen Spurrier · Epicentre · Evgeniy Grigoriev, Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation · Evgeniy Rosseykin, Federal Center of Cardiovascular Surgery, Khabarovsk, Russian Federation · FDA Office of Orphan Products Development · Fabio Savorgnan · Fernando Suarez Sipmann · Fudan University · Fundación Cardiovascular de Colombia · Fundación Santandereana de Diabetes y Obesidad (FUSANDE) · Grigoryev Evgeny, Scientific Research Insitute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia. · Harvard Medical School (HMS and HSDM) · Heart and Stroke Foundation of Canada · Hunan Children's Hospital · Ichinose, Fumito, M.D., Ph.D., Massachusetts General Hospital · Indiana University · Insel Gruppe AG, University Hospital Bern · Instituto de Salud de Bucaramanga · Jennifer En-Sian Ho M.D., Massachusetts General Hospital · Jia Min, The First Affiliated Hospital of Nanchang University, Nanchang, China. · Jiange Han, Tianjin Chest Hospital, Tianjin, China · Jiawan Wang, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China · Jing Shi, The Afffliated Hospital of Guizhou Medical University, Guiyang, China. · Kacmarek, Robert M., Ph.D., Massachusetts General Hospital · Kenneth, Shelton, M.D., Massachusetts General Hospital · Loma Linda University · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Lorenzo Berra., M.D., Massachusetts General Hospital · Makerere University · Maternite Regionale Universitaire · Mbarara University of Science and Technology · Medecins Sans Frontieres, Netherlands · all 137 on the full record

Regulatory milestones approvals, filings & regulatory actions · 4 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (2)	US (FDA)	INOMAX	—	2010-12-21 – 2015-10-09	fda.gov ↗
Approved	EU (EMA)	INOmax	—	2001-08-01	europa.eu ↗
Approved	US (FDA)	INOMAX	—	1999-12-23	fda.gov ↗

Trials 124 · started per year

today

US approved 1999

EU approved 2001

1992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 06 trials · 1 met primary
Phase 0	NCT06950294	Feb → Dec 2026 expected	pneumonia	Massachusetts General Hospital	Recruiting	No outcome recorded
Phase 0	NCT06249633	Feb 2024 → Feb 2026	acute respiratory distress syndrome, pulmonary hypertension	Yuri Matusov	Unknown	No outcome recorded
Phase 0	NCT05612074	Oct 2023 → Nov 2026 expected	—	Massachusetts General Hospital	Active not recruiting	No outcome recorded
Phase 0	NCT04069052	Sep 2021 → May 2023	chronic obstructive pulmonary disease	Dr. Denis O'Donnell	Completed	No outcome recorded
Phase 0	NCT04134078	Aug 2016 → Jul 2020	cardiac arrest	Stony Brook University	Unknown	Met primary
Phase 0	NCT02220023	Jul 2014 → Feb 2017	pulmonary hypertension	Vanderbilt University	Completed	No outcome recorded
Phase 18 trials
Phase 1	NCT06120816	Jan → May 2024	oral candidiasis	Sanotize Research and Development corp.	Completed	No outcome recorded
Phase 1	NCT05351502	Aug 2022 → May 2025 overdue	cancer	Beyond Air Inc.	Recruiting	No outcome recorded
Phase 1	NCT03946462	Oct 2021 → Oct 2022	acute kidney injury, congenital heart disease	Fabio Savorgnan	Withdrawn	No outcome recorded
Phase 1	NCT04383002	Sep 2020 → May 2021	COVID-19	University Health Network, Toronto	Completed	No outcome recorded
Phase 1	NCT00848731	Feb 2009 → May 2011	pulmonary embolism	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 1	NCT00352430	Jul 2006 → Mar 2010	pulmonary hypertension	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 1	NCT00023296	Jul 2001 → Nov 2006	pulmonary hypertension, sickle cell disease	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 1	NCT00001303	Apr 1992 → Mar 2007	infectious disease with sepsis, lung disorder	National Institutes of Health Clinical Center (CC)	Completed	No outcome recorded
Phase 1/214 trials · 2 met primary · 2 missed
Phase 1/2	NCT04231760	Dec 2026 → Dec 2027 expected	chronic obstructive pulmonary disease	University of Alberta	Not yet recruiting	No outcome recorded
Phase 1/2	NCT04181359	Sep 2024 → Dec 2025	—	University of Alberta	Withdrawn	No outcome recorded
Phase 1/2	NCT04231773	Aug 2020 → Dec 2021	—	University of Alberta	Completed	No outcome recorded
Phase 1/2	NCT04476992	Jul 2020 → Jul 2021	COVID-19, polycythemia due to hypoxia, viral pneumonia	Tomsk National Research Medical Center of the Russian Academy of Sciences	Completed	Met primary
Phase 1/2	NCT03679312	Sep 2018 → Nov 2023	—	University of Alberta	Completed	Missed primary
Phase 1/2	NCT03527381	Sep 2015 → Dec 2016	acute kidney injury, cardiomyopathy, coronary artery disorder, heart valve disorder	Nikolay Kamenshchikov	Completed	Met primary
Phase 1/2	NCT03500783	May 2015 → Nov 2016	coronary artery disorder	Tomsk National Research Medical Center of the Russian Academy of Sciences	Completed	No outcome recorded
Phase 1/2	NCT01958944	Dec 2013 → Nov 2015	cystic fibrosis	Beyond Air Inc.	Completed	No outcome recorded
Phase 1/2	NCT01768884	Jan 2013 → Jan 2016	bronchiolitis	Beyond Air Inc.	Completed	No outcome recorded
Phase 1/2	NCT01255215	Jul 2011 → Jul 2013	malaria	University Health Network, Toronto	Completed	Missed primary
Phase 1/2	NCT00771368	Jan → May 2009	decubitus ulcer, ulcer of lower limbs	Nitric BioTherapeutics, Inc	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT00585013	Jan 2008 → Jun 2011	congenital heart disease	Washington University School of Medicine	Completed	Mixed
Phase 1/2	NCT00570349	Jul 2004 → Dec 2008	cystic fibrosis	Mallinckrodt	Completed	No outcome recorded
Phase 1/2	NCT00041548	May 2002 → Jun 2005	acidosis disorder, lung disorder	Mallinckrodt	Terminated	No outcome recorded Stop: Enrollment

Phase 246 trials · 1 met primary · 2 missed
Phase 2	NCT05616910	Apr 2025 → Mar 2028 expected	traumatic brain injury	University of Pennsylvania	Enrolling by invitation	No outcome recorded
Phase 2	NCT05721144	Feb 2023 → Apr 2024	COVID-19	Xijing Hospital	Completed	No outcome recorded
Phase 2	NCT04290871	Jan → Dec 2023	severe acute respiratory syndrome	Xijing Hospital	Withdrawn	No outcome recorded Stop: Enrollment
Phase 2	NCT05868109	Aug 2022 → Jan 2025	cardiac arrest	The Hospital for Sick Children	Unknown	No outcome recorded
Phase 2	NCT04443868	Jan → Apr 2021	COVID-19	Sanotize Research and Development corp.	Withdrawn	No outcome recorded Stop: Enrollment
Phase 2	NCT04398290	Dec 2020 → Jun 2021	COVID-19, respiratory failure	Roger Alvarez	Withdrawn	No outcome recorded
Phase 2	NCT04456088	Jul → Nov 2020	COVID-19, viral pneumonia	Beyond Air Inc.	Withdrawn	No outcome recorded
Phase 2	NCT04388683	May → Nov 2020	COVID-19	Tufts Medical Center	Terminated	No outcome recorded
Phase 2	NCT04338828	Apr 2020 → Jan 2021	COVID-19	Massachusetts General Hospital	Terminated	No outcome recorded
Phase 2	NCT04312243	Apr 2020 → Jan 2022	Orthocoronavirinae infectious disease, nosocomial infection	Massachusetts General Hospital	Terminated	No outcome recorded
Phase 2	NCT04305457	Mar 2020 → Aug 2023	COVID-19, acute respiratory distress syndrome, viral pneumonia	Massachusetts General Hospital	Terminated	No outcome recorded
Phase 2	NCT04306393	Mar 2020 → Dec 2021	severe acute respiratory syndrome	Massachusetts General Hospital	Completed	No outcome recorded
Phase 2	NCT04290858	Mar 2020 → Mar 2021	COVID-19, viral pneumonia	Xijing Hospital	Withdrawn	No outcome recorded
Phase 2	NCT04060979	Nov 2019 → Mar 2020	acute bronchiolitis	Beyond Air Inc.	Completed	Met primary
Phase 2	NCT04163978	Oct 2019 → May 2022	chronic rhinosinusitis	Sanotize Research and Development corp.	Completed	No outcome recorded
Phase 2	NCT04022161	Jul 2019 → Nov 2025	cardiovascular disorder	Massachusetts General Hospital	Withdrawn	No outcome recorded Stop: Business
Phase 2	NCT03748082	Dec 2018 → Nov 2023	anemia, nonspherocytic hemolytic, cardiovascular disorder	Massachusetts General Hospital	Withdrawn	No outcome recorded Stop: Business
Phase 2	NCT03473314	Mar 2018 → Jul 2020	pulmonary non-tuberculous mycobacterial infection	University of British Columbia	Completed	No outcome recorded
Phase 2	NCT05747508	Dec 2017 → Nov 2019	pulmonary fibrosis, pulmonary hypertension	Bellerophon	Unknown	No outcome recorded
Phase 2	NCT03331445	Oct 2017 → Jun 2021	COVID-19, respiratory tract infectious disorder	Nitric Solutions Inc.	Terminated	No outcome recorded Stop: Business
Phase 2	NCT03079102	Aug 2017 → May 2020	cardiac arrest	Cameron Dezfulian	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT03208764	Jul 2017 → May 2018	mycobacterial infectious disease	Beyond Air Inc.	Completed	No outcome recorded
Phase 2	NCT03023449	Apr 2017 → Mar 2021 overdue	stroke disorder	Steven Messe	Active not recruiting	No outcome recorded
Phase 2	NCT02498535	Feb 2017 → Jun 2020	cystic fibrosis	Novoteris, LLC	Terminated	No outcome recorded
Phase 2	NCT02871011	Aug → Nov 2016	tinea pedis	Nitric Solutions Inc.	Completed	No outcome recorded
Phase 2	NCT02734953	Apr → Aug 2016	pulmonary arterial hypertension	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)	Completed	No outcome recorded
Phase 2	NCT02345616	Feb 2015 → Dec 2019	pulmonary hypertension	University Hospital, Clermont-Ferrand	Unknown	No outcome recorded
Phase 2	NCT01728220	Dec 2012 → Jun 2014	chronic obstructive pulmonary disease, pulmonary hypertension	Bellerophon Pulse Technologies	Completed	No outcome recorded
Phase 2	NCT01457781	Apr 2012 → Oct 2014	pulmonary arterial hypertension	Bellerophon Pulse Technologies	Completed	No outcome recorded
Phase 2	NCT01529502	Mar 2012 → Dec 2013	pulmonary hypertension	Massachusetts General Hospital	Completed	No outcome recorded
Phase 2	NCT01388842	Sep 2011 → Feb 2014	cerebral malaria	Epicentre	Completed	No outcome recorded
Phase 2	NCT01265888	Mar 2011 → Sep 2016	idiopathic pulmonary fibrosis, pulmonary arterial hypertension	Geno LLC	Completed	No outcome recorded
Phase 2	NCT01092559	Oct 2010 → Jul 2011	pulmonary arterial hypertension	Geno LLC	Completed	No outcome recorded
Phase 2	NCT01165047	Sep 2010 → Sep 2011	pulmonary arterial hypertension	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 2	NCT00893880	Jun 2009 → Jan 2010	tinea pedis	Nitric BioTherapeutics, Inc	Completed	No outcome recorded
Phase 2	NCT00790608	Jan → May 2009	methicillin-resistant staphylococcus aureus infectious disease, ulcer disease	Nitric BioTherapeutics, Inc	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00771342	Dec 2008 → Jun 2009	tinea infection	Nitric BioTherapeutics, Inc	Completed	No outcome recorded
Phase 2	NCT00545298	Oct 2007 → Nov 2008	ulcer of lower limbs	Nitric BioTherapeutics, Inc	Terminated	No outcome recorded Stop: Business
Phase 2	NCT00955487	Jan 2007 → Jul 2014	bronchopulmonary dysplasia	University of Colorado, Denver	Completed	Missed primary
Phase 2	NCT00568061	Jun 2006 → Jun 2008	ST-elevation myocardial infarction	Mallinckrodt	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00823095	Dec 2005 → Oct 2008	ulcer of lower limbs	Loma Linda University	Terminated	No outcome recorded
Phase 2	NCT00142051	Apr 2005 → Aug 2013	sickle cell disease	Boston Children's Hospital	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00565253	Mar 2005 → Jul 2009	pulmonary embolism	Medical University of Vienna	Completed	No outcome recorded
Phase 2	NCT00094887	Oct 2004 → Dec 2008	sickle cell disease	Mallinckrodt	Completed	Missed primary
Phase 2	NCT00014040	Apr 2001 → Apr 2003	coronary artery disorder, myocardial ischemia	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 2	NCT00001716	Jul 1998 → Jul 2003	intermediate coronary syndrome, sickle cell disease	National Institutes of Health Clinical Center (CC)	Completed	No outcome recorded

Phase 2/38 trials · 1 met primary · 1 missed
Phase 2/3	NCT05101746	Apr 2022 → Sep 2026 overdue	congenital heart disease, congenital heart malformation	Vanderbilt University Medical Center	Enrolling by invitation	No outcome recorded
Phase 2/3	NCT04259684	Oct 2019	acute kidney injury, congenital heart disease	Children's Hospital Medical Center, Cincinnati	Withdrawn	No outcome recorded
Phase 2/3	NCT03455218	Apr 2018 → Apr 2019	platelet disorder, undefined	Medical College of Wisconsin	Completed	No outcome recorded
Phase 2/3	NCT01748045	Mar 2013 → Jul 2014	bronchopulmonary dysplasia	Tufts Medical Center	Terminated	No outcome recorded Stop: Enrollment
Phase 2/3	NCT01503801	May 2011 → Sep 2012	lung disorder	Fudan University	Completed	No outcome recorded
Phase 2/3	NCT00748423	Dec 2008 → Dec 2012	acute chest syndrome, sickle cell disease	Assistance Publique - Hôpitaux de Paris	Completed	Missed primary
Phase 2/3	NCT00582010	Apr 2008 → Mar 2009	liver disorder	University of Alabama at Birmingham	Completed	Met primary
Phase 2/3	NCT00945529	Feb 2008 → Dec 2011	congenital heart disease	Ellen Spurrier	Completed	No outcome recorded
Phase 322 trials · 3 met primary · 8 missed
Phase 3	NCT06702553	May 2025 → Mar 2028 expected	—	Xijing Hospital	Recruiting	No outcome recorded
Phase 3	NCT04216927	Jan 2023 → Jun 2026 overdue	acute kidney injury, congenital heart disease	Children's Hospital Medical Center, Cincinnati	Recruiting	No outcome recorded
Phase 3	NCT04807413	Aug 2021 → Apr 2023	—	Rabin Medical Center	Unknown	Met primary
Phase 3	NCT05012319	Aug 2021 → Mar 2022	COVID-19	Salmaniya Medical Complex	Unknown	Met primary
Phase 3	NCT03267108	Dec 2020 → Jun 2023	pulmonary fibrosis, pulmonary hypertension	Bellerophon Pulse Technologies	Terminated	Missed primary
Phase 3	NCT04421508	Jul → Dec 2020	COVID-19	Bellerophon Pulse Technologies	Terminated	Missed primary
Phase 3	NCT03053388	Mar 2017 → Apr 2018	acute bronchiolitis	Beyond Air Inc.	Completed	No outcome recorded
Phase 3	NCT02836899	Feb 2017 → Aug 2025	acute kidney injury	Massachusetts General Hospital	Completed	Missed primary
Phase 3	NCT02725372	Apr 2016 → Aug 2018	pulmonary arterial hypertension	Bellerophon Pulse Technologies	Terminated	Missed primary
Phase 3	NCT02436512	Jun → Aug 2015	pulmonary arterial hypertension	Geno LLC	Withdrawn	No outcome recorded Stop: Enrollment
Phase 3	NCT01607983	Jun 2012 → Dec 2017	congenital heart disease	University of California, San Francisco	Withdrawn	No outcome recorded Stop: Enrollment
Phase 3	NCT00922532	Nov 2009 → Oct 2011	pulmonary hypertension owing to lung disease and/or hypoxia	Mallinckrodt	Withdrawn	No outcome recorded
Phase 3	NCT00608322	Aug 2009 → Apr 2013	infectious disease with sepsis	National Institute of General Medical Sciences (NIGMS)	Completed	Missed primary
Phase 3	NCT00152542	May 2005 → Sep 2006	respiratory distress syndrome in premature infants	University of Chicago	Completed	No outcome recorded
Phase 3	NCT00428727	Jan 2005 → Feb 2011	—	Fundación Cardiovascular de Colombia	Completed	No outcome recorded
Phase 3	NCT00626028	Sep 2004 → Feb 2010	cardiomyopathy, idiopathic pulmonary arterial hypertension	Mallinckrodt	Completed	Mixed
Phase 3	NCT00041561	Jan 2002 → Dec 2004	acute respiratory failure	Mallinckrodt	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00060450	Aug 2001 → Sep 2006	ischemic disease	Mallinckrodt	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00016523	Jan 2001 → Sep 2003	fetal growth restriction, infectious disease with sepsis, pneumonia, pulmonary hypertension +1	NICHD Neonatal Research Network	Terminated	Missed primary
Phase 3	NCT00006401	Sep 2000 → Sep 2005	bronchopulmonary dysplasia, lung disorder	University of Colorado, Denver	Completed	Missed primary
Phase 3	NCT00005773	Aug 1998 → May 2001	aspiration pneumonia, newborn respiratory distress syndrome, persistent fetal circulation syndrome, pulmonary hypertension	NICHD Neonatal Research Network	Terminated	Missed primary Stop: Enrollment
Phase 3	NCT00005776	Oct 1995 → May 1996	aspiration pneumonia, newborn respiratory distress syndrome, persistent fetal circulation syndrome, pulmonary hypertension	NICHD Neonatal Research Network	Terminated	Met primary

Phase 46 trials · 1 missed
Phase 4	NCT07247240	Nov 2025 → Dec 2028 expected	congenital diaphragmatic hernia, pulmonary hypertension	Asan Medical Center	Not yet recruiting	No outcome recorded
Phase 4	NCT06622291	Nov 2024 → Nov 2025	acute kidney injury, aortic aneurysm	Beijing Anzhen Hospital	Completed	No outcome recorded
Phase 4	NCT03044314	Jul 2017 → Jun 2019	pulmonary hypertension	Duke University	Terminated	Missed primary Stop: Enrollment
Phase 4	NCT01717209	Oct 2012 → Oct 2013	heart failure	Stanford University	Completed	No outcome recorded
Phase 4	NCT00390065	Oct 2006 → Jun 2009	—	Maternite Regionale Universitaire	Completed	No outcome recorded
Phase 4	NCT00732537	Mar 1999 → Jun 2005	persistent fetal circulation syndrome, respiratory failure	University of Alabama at Birmingham	Completed	No outcome recorded
Phase not applicable12 trials · 1 missed
—	NCT07639931	Jul 2026 → Dec 2028 expected	acute mountain sickness, high altitude pulmonary edema	Tibet Autonomous Region People's Hospital	Not yet recruiting	No outcome recorded
—	NCT07544147	Apr 2026 → Oct 2028 expected	acute kidney injury	Shanghai Zhongshan Hospital	Not yet recruiting	No outcome recorded
—	NCT07125443	Sep 2025 → Dec 2026 expected	liver disorder, vascular disorder	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Not yet recruiting	No outcome recorded
—	NCT06739538	Mar → Sep 2024 overdue	cerebral palsy	Superior University	Active not recruiting	No outcome recorded
—	NCT06261827	Feb 2024 → May 2025	bacterial pneumonia	Tomsk National Research Medical Center of the Russian Academy of Sciences	Completed	No outcome recorded
—	NCT06170372	Jan 2024 → Jan 2026 overdue	pneumonia	Tomsk National Research Medical Center of the Russian Academy of Sciences	Recruiting	No outcome recorded
—	NCT06213077	Dec 2023 → Apr 2024	erectile dysfunction	RHA Investments Ltd	Unknown	No outcome recorded
—	NCT06097026	Nov 2023 → Aug 2024	pneumothorax	Fernando Suarez Sipmann	Unknown	No outcome recorded
—	NCT03009643	Oct 2016 → Oct 2019	—	Shanghai Zhongshan Hospital	Unknown	No outcome recorded
—	NCT02151877	Jul 2014 → Aug 2018	—	Wake Forest University Health Sciences	Completed	Missed primary
—	NCT04988932	Jul 2012 → Jul 2019	acquired aneurysmal subarachnoid hemorrhage, brain ischemia, intracranial vasospasm	Insel Gruppe AG, University Hospital Bern	Completed	No outcome recorded
—	NCT00948194	Oct 2009 → Dec 2015	ischemic disease	University of Colorado, Denver	Terminated	No outcome recorded

Phase not stated2 trials
—	NCT04358588	—	COVID-19, viral pneumonia	Bellerophon	No longer available	No outcome recorded
—	NCT05356052	—	pulmonary fibrosis, pulmonary hypertension	Bellerophon	Available	No outcome recorded
Comparator or background therapy27 trials
Phase 0	NCT05052229 Comparator	Apr 2022 → Dec 2024	idiopathic pulmonary fibrosis	Dr. Denis O'Donnell	Unknown	No outcome recorded
Phase 1	NCT02267655 Comparator	May 2015 → Jun 2017	chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, pulmonary hypertension	Bellerophon	Completed	No outcome recorded
Phase 1	NCT00159510 Comparator	Apr 2004 → Sep 2014	infectious disease with sepsis	Northern State Medical University	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT04601077 Comparator	Nov 2020 → Nov 2022	COVID-19	Nitric Oxide Innovations LLC	Terminated	No outcome recorded
Phase 1/2	NCT03576885 Comparator	Jul 2019 → Oct 2023	bronchopulmonary dysplasia, pulmonary hypertension	AdventHealth	Terminated	No outcome recorded
Phase 1/2	NCT01351493 Comparator	Jul 2012 → Jul 2013	decubitus ulcer	China Medical University Hospital	Unknown	No outcome recorded
Phase 2	NCT04996667 Comparator	Jun 2026 → Dec 2027	pulmonary embolism	University of California, Los Angeles	Withdrawn	No outcome recorded
Phase 2	NCT05877313 Comparator	Aug 2023 → Feb 2024	plantar wart	Sanotize Research and Development corp.	Completed	No outcome recorded
Phase 2	NCT02217683 Comparator	Mar → Dec 2016	hemolytic anemia, pulmonary hypertension	Massachusetts General Hospital	Withdrawn	No outcome recorded Stop: Business
Phase 2	NCT01939301 Comparator	Oct 2013 → Oct 2016	pulmonary embolism	Indiana University	Completed	No outcome recorded
Phase 2	NCT02295566 Comparator	May 2011 → Dec 2012	cystic fibrosis	University Hospital Southampton NHS Foundation Trust	Completed	No outcome recorded
Phase 2	NCT01398384 Comparator	Oct 2010 → May 2014	acute myocardial infarction	Universitaire Ziekenhuizen KU Leuven	Completed	No outcome recorded
Phase 2	NCT01089439 Comparator	Jun 2010 → Nov 2013	acute chest syndrome, sickle cell disease	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT00613808 Comparator	Feb → Nov 2008	ulcer of lower limbs	Nitric BioTherapeutics, Inc	Terminated	No outcome recorded
Phase 2	NCT00782652 Comparator	Mar 2006 → Feb 2007	myocardial infarction	Mallinckrodt	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00570245 Comparator	Apr 2005 → Jun 2008	—	Mallinckrodt	Completed	No outcome recorded
Phase 2	NCT00060840 Comparator	Jul 2003 → Jun 2008	congestive heart failure	Mallinckrodt	Completed	No outcome recorded
Phase 3	NCT05109611 Comparator	Nov 2021 → Jan 2024	COVID-19	Sanotize Research and Development corp.	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT05599919 Comparator	Nov 2021 → Jan 2022	COVID-19	Sanotize Research and Development corp.	Completed	No outcome recorded
Phase 3	NCT03260569 Comparator	Dec 2018 → Dec 2023	traumatic brain injury	University of Cincinnati	Completed	No outcome recorded
Phase 3	NCT03661385 Comparator	Jul 2018 → Mar 2022	cardiogenic shock, transposition of the great arteries	Murdoch Childrens Research Institute	Completed	No outcome recorded
Phase 3	NCT00551642 Comparator	May 2005 → Mar 2008	lung disorder	Mallinckrodt	Completed	No outcome recorded
Phase 3	NCT00240487 Comparator	Sep 2000 → Sep 2008	pediatric acute respiratory distress syndrome	Children's Hospital of Philadelphia	Completed	No outcome recorded
Phase 4	NCT04231084 Comparator	Jan 2021 → Aug 2024	pulmonary hypertension	Brigham and Women's Hospital	Completed	No outcome recorded
Phase 4	NCT03081052 Comparator	May 2017 → Oct 2020	—	Duke University	Completed	No outcome recorded
—	NCT05587400 Background	Jul 2022 → Dec 2024	pulmonary arterial hypertension	Shanghai Zhongshan Hospital	Unknown	No outcome recorded
—	NCT04920695 Comparator	May 2021 → May 2023	pulmonary embolism	Dr. Denis O'Donnell	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 48

Date	Issuer	Release
2026-04-20	Beyond Air Inc.	Results Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026 beyondair.net ↗
2026-03-17	Beyond Air Inc.	Results Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial beyondair.net ↗ As of October 1, 2025, seven of ten patients remain alive between 19 to 37 months following a single UNO injection.
2025-06-16	Beyond Air Inc.	Regulatory Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH beyondair.net ↗ Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH
2025-04-09	Beyond Air Inc.	Results Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home beyondair.net ↗ In this pilot study, the delivery of high dose iNO treatments at home revealed high compliance with a favorable safety profile, potential quality of life improvement, and decreased culture score implying a decrease in mycobacterial load.
2025-01-24	Beyond Air Inc.	Regulatory Beyond Air® Announces LungFit® PH Receives Market Authorization in Australia beyondair.net ↗ We are excited to have the opportunity to introduce our revolutionary LungFit PH system to hospitals in Australia following this market authorization by the TGA.
2024-12-03	Beyond Air Inc.	Regulatory Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy beyondair.net ↗ today announced that the Israeli Ministry of Health (IMOH) has approved the use of Low Volume UNO (LV UNO) in a Phase 1b clinical trial of LV UNO in combination with anti-PD-1 therapy.
2024-12-02	Beyond Air Inc.	Regulatory Beyond Air Receives CE Mark in Europe for the LungFit® PH System beyondair.net ↗ Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced European CE mark approval of the LungFit ® PH system.
2024-11-11	Beyond Air Inc.	Results Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting beyondair.net ↗ In a study using MAT B III tumor-bearing rats, LV UNO combined with anti-rPD-L1 doubled the tumor growth inhibition rate and led to improved survival outcomes compared to anti-rPD-L1 alone.
2024-10-07	Beyond Air Inc.	Results Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting beyondair.net ↗ Intratumoral Administration of Low Volume High-Concentration Nitric Oxide and Anti-rPD-L1 Treatment Leads to Prolonged Survival in MAT B III Tumor-Bearing Rats
2024-07-31	Beyond Air Inc.	Results Beyond Air® Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia beyondair.net ↗ We are pleased to publish these promising data showing 150-ppm intermittent inhaled NO administered with the LungFit ® PRO device is well-tolerated, safe, and beneficial compared to usual care in treating adults hospitalized for viral pneumonia due to COVID-19.
2024-06-03	Beyond Air Inc.	Results Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO) beyondair.net ↗ Beyond Cancer, Ltd., a clinical-stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, announced encouraging first-in-class clinical data demonstrating evidence of immune system activation via biomarker response in a heavily pretreated population in the ongoing Phase 1a trial.
2023-12-27	Beyond Air Inc.	Results Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors beyondair.net ↗ No dose limiting toxicities were reported in the first cohort of ultra-high concentration of nitric oxide administered at 25,000 parts per million (PPM)
2023-11-03	Beyond Air Inc.	Results Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting beyondair.net ↗ First-in-human Phase 1 study demonstrates early clinical proof of concept
2023-10-17	Beyond Air Inc.	Results Beyond Cancer™ Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in Mice beyondair.net ↗ Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, announced today the publication of pre-clinical data demonstrating that its proprietary technology reduces immunosuppression and creates a favorable microenvironment that can contribute to immune potentiation.
2023-10-04	Beyond Air Inc.	Results Beyond Cancer™ Selected to Present Proffered Posters Discussing Data from the UNO Therapy Program at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics beyondair.net ↗ Intratumoral Administration of Ultra High-Concentration Nitric Oxide (UNO) and Anti PD-1 Treatment Leads to High Tumor Regression Rates and Prolonged Survival in Tumor-Bearing Mice
2023-09-18	Beyond Air Inc.	Results Beyond Air® Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder beyondair.net ↗ New data demonstrates a therapeutic effect for at least 10 days after a single subcutaneously (SC) injection of an extended-release selective neuronal nitric oxide synthase (nNOS) inhibitor
2023-08-07	Beyond Air Inc.	Results Beyond Air® Announces Positive Preclinical Data on Role of Nitric Oxide in Autism Spectrum Disorder (ASD) beyondair.net ↗ Research conducted recently at HUJI has shown that mutation in the CNTNAP2 gene increases NO formation in the brain of the ASD mouse model.
2023-04-19	Beyond Air Inc.	Results Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the American Association for Cancer Research (AACR) 2023 Annual Meeting beyondair.net ↗ Data showed a statistically significant survival benefit for repeat dosing of UNO compared to anti-CTLA-4 as a monotherapy and in combination with anti-PD-1 compared to anti-PD-1 alone.
2022-12-13	Beyond Air Inc.	Results Beyond Cancer® Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Method Utilizing Ultra-High Concentration Nitric Oxide (UNO) Induced a Systemic Response that Prevents Metastases beyondair.net ↗ Data describe a potent systemic immune response resulting in a significant reduction in challenge tumors and improvement in survival for UNO treated mice
2022-11-10	Beyond Air Inc.	Results Beyond Cancer™ Presents Promising New In Vivo Data Showing Ultra-High Concentration Nitric Oxide Therapy (UNO) in Combination with Anti-PD-1 During the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting beyondair.net ↗
2022-10-24	Beyond Air Inc.	Results Beyond Air® Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVID-19 with LungFit® PRO in a Poster Presentation at IDWeek 2022 beyondair.net ↗ Beyond Air® Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVID-19 with LungFit® PRO in a Poster Presentation at IDWeek 2022
2022-10-17	Beyond Air Inc.	Results Beyond Air® Announces Positive Data from At-Home Pilot Study in Patients with Refractory NTM Lung Infection Treated with (NO) using the LungFit® GO at the CHEST Annual Meeting 2022 beyondair.net ↗
2022-10-05	Beyond Air Inc.	Results Beyond Cancer™ to Present Pre-Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2022 SITC Annual Meeting beyondair.net ↗ Intratumoral Administration of High-Concentration Nitric Oxide and Anti PD-1 Treatment Leads to Higher Tumor Regression Rates and Prolonged Survival in CT26 Tumor-Bearing Mice
2022-10-03	Beyond Air Inc.	Results Beyond Air® Announces that Annals of the American Thoracic Society Published a Review of the Third Pilot Study of High Dose Nitric Oxide for Bronchiolitis beyondair.net ↗ The results of this study show that high dose inhaled NO given intermittently may be useful in treating patients with moderate to severe bronchiolitis, and supports the need to conduct a larger, confirmatory efficacy study.
2022-07-13	Glenmark Pharmaceuticals Ltd. India	Results Glenmark Pharmaceuticals and SaNOtize Announce Peer Reviewed Publication of Its Phase 3 Clinical Trials on SaNOtize’s Novel Nitric Oxide Nasal Spray for COVID-19 in Lancet Journal glenmarkpharma.com ↗ The Lancet Regional Health Southeast Asia publishes the successful phase 3 clinical trial results of Nitric Oxide Nasal Spray.
2022-06-28	Beyond Air Inc.	Regulatory Beyond Air's LungFit® PH Receives FDA Approval to Treat Term and Near-Term Neonates with Hypoxic Respiratory Failure beyondair.net ↗ Beyond Air's LungFit® PH Receives FDA Approval to Treat Term and Near-Term Neonates with Hypoxic Respiratory Failure
2022-05-17	Beyond Air Inc.	Results Beyond Air® Presents Positive Study Update from the At-Home LungFit® GO Pilot Study for Nontuberculous Mycobacterial Lung Disease at the American Thoracic Society International Conference 2022 beyondair.net ↗ Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced positive new interim data from the ongoing LungFit® GO pilot at-home study in Australia.
2022-04-25	Beyond Air Inc.	Results Beyond Air® Reports Positive Long-Term Safety Data for High Concentration Inhaled Nitric Oxide in Bronchiolitis at the Pediatric Academic Societies Meeting 2022 beyondair.net ↗ Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced positive long-term safety data for high concentration inhaled NO for the treatment of bronchiolitis.
2022-04-25	Beyond Air Inc.	Results Beyond Air® Presents Positive Safety and Efficacy Data for Inhaled Nitric Oxide to Treat COVID-19 at ECCMID 2022 beyondair.net ↗ Inhaled NO treatment in patients hospitalized with COVID-19 and other community-acquired viral pneumonia was well tolerated overall, and safe, with improved efficacy parameters as compared to standard supportive treatment
2022-04-11	Beyond Air Inc.	Results Beyond Cancer™ Announces New Preclinical Data Presented at American Association for Cancer Research (AACR) Showing Ultra-High Concentration Nitric Oxide Therapy Anti-Tumor Effect beyondair.net ↗ Data suggests ultra-high concentration gaseous NO (gNO) induced both innate and adaptive immune cell populations, and a decline in immune suppressor cells, which are indicative of an anti-tumor immune response
2021-10-20	Beyond Air Inc.	Results Beyond Air® Reports Positive Interim Results for LungFit® GO Pilot Study Using High Concentration Inhaled Nitric Oxide Self-Administered, At-Home for Nontuberculous Mycobacterial Lung Disease beyondair.net ↗ Interim results show that 250 parts per million (ppm) nitric oxide (NO) was well-tolerated with no study discontinuations or treatment-related serious adverse events observed
2021-05-13	Beyond Air Inc.	Results Beyond Air® Presents Data in Hospitalized Patients with Viral Lung Infections (including COVID-19) from LungFit® PRO Programs at ATS 2021 beyondair.net ↗
2020-11-11	Beyond Air Inc.	Regulatory Beyond Air® Submits Premarket Approval Application to FDA for LungFit™ PH to Treat Persistent Pulmonary Hypertension of the Newborn beyondair.net ↗ Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced the submission of a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its LungFit™ PH to treat persistent pulmonary hypertension of the newborn (PPHN).
2020-10-21	Beyond Air Inc.	Regulatory Beyond Air® Approved to Initiate Clinical Study at 150 ppm Nitric Oxide with LungFit™ for the Treatment of Acute Viral Pneumonia Including COVID-19 beyondair.net ↗ Beyond Air® Approved to Initiate Clinical Study at 150 ppm Nitric Oxide with LungFit™ for the Treatment of Acute Viral Pneumonia Including COVID-19
2020-10-19	Beyond Air Inc.	Results Beyond Air® Presents In Vivo Solid Tumor Data Confirming In Situ Cancer Vaccination with a Single Injection of Gaseous Nitric Oxide at the AACR Conference on Tumor Immunology and Immunotherapy beyondair.net ↗ New in vivo data for colon cancer show anti-tumor immunity in 100% of mice
2020-10-19	Beyond Air Inc.	Results Beyond Air® Presents Pilot Bronchiolitis Data at the CHEST Annual Meeting 2020 beyondair.net ↗ 150 ppm nitric oxide was statistically significant compared to both control and 85 ppm nitric oxide arms on the primary and key secondary endpoints
2020-10-19	Beyond Air Inc.	Results Beyond Air® Presents Data Showing Anti-Coronavirus Activity of Nitric Oxide at the CHEST Annual Meeting 2020 beyondair.net ↗ Exposure of OC43 human coronavirus infected cells to 150-250 ppm NO intermittent exposure regimens (4 one-hour exposures over 7 hours) resulted in as much as a 46% increase in host cell viability
2020-10-16	Beyond Air Inc.	Results Beyond Air® Presents Positive New Preclinical Data for the Use of a Single Injection of Gaseous Nitric Oxide as a Novel In situ Cancer Vaccination beyondair.net ↗ Beyond Air® Presents Positive New Preclinical Data for the Use of a Single Injection of Gaseous Nitric Oxide as a Novel In situ Cancer Vaccination
2020-08-10	Beyond Air Inc.	Results Beyond Air Publishes New Data on Nitric Oxide to Treat M. Abscessus in the Peer-Reviewed Journal Access Microbiology beyondair.net ↗ Longer treatment regimens could be required to see reduction or eradication of more resistant pulmonary strains
2020-06-22	Beyond Air Inc.	Results Beyond Air Announces Positive Preclinical Data Supporting High Concentration Nitric Oxide as a Potential Treatment for Solid Tumors beyondair.net ↗ Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced in vivo and in vitro data that show the potential efficacy of high concentration nitric oxide in ablation of solid tumors.
2020-06-15	Beyond Air Inc.	Results Beyond Air Announces Publication of Peer-Reviewed Journal Article in Scientific Reports beyondair.net ↗ The encouraging results of this study, which strengthens our previous published data, indicate that NO is safe and efficacious in hospitalized infants with bronchiolitis and may be considered in patients with lower respiratory tract infections.
2020-05-26	Beyond Air Inc.	Regulatory Beyond Air Receives Approval from Health Canada to Study Nitric Oxide Generated and Delivered by the LungFit™ in COVID-19 Patients beyondair.net ↗
2020-05-20	Beyond Air Inc.	Results Beyond Air Achieves Primary Endpoint in Pilot Bronchiolitis Study beyondair.net ↗
2020-05-15	Beyond Air Inc.	Results Beyond Air™ to Present New Data in an e-Poster Presentation at the Upcoming AACR Virtual Annual Meeting II on June 22nd to 24th beyondair.net ↗ The preclinical data show the potential effectiveness of high concentration nitric oxide in treating various solid tumors.
2020-04-16	Beyond Air Inc.	Regulatory Beyond Air to Initiate Clinical Study Evaluating High Concentration Nitric Oxide for the Treatment of COVID-19 Patients in the United States beyondair.net ↗ today announced that the U.S. Food and Drug Administration (FDA) agreed with the initiation of a clinical study in the U.S. using its LungFit TM system to treat COVID-19 patients.
2020-03-16	Beyond Air Inc.	Regulatory Beyond Air Submits Investigational Device Exemption (IDE) to the United States Food and Drug Administration (FDA) for the Treatment of COVID-19 Patients beyondair.net ↗ Beyond Air Submits Investigational Device Exemption (IDE) to the United States Food and Drug Administration (FDA) for the Treatment of COVID-19 Patients
2019-10-16	Beyond Air Inc.	Results Beyond Air™ Provides Update on High Concentration Nitric Oxide (NO) Animal Studies Using LungFit™ beyondair.net ↗ Results from the 30-day study demonstrated clean safety results with no unexpected findings.
2019-10-01	Beyond Air Inc.	Results Beyond Air™ Presents Data at the 2019 European Respiratory Society (ERS) International Congress in Madrid, Spain beyondair.net ↗ Dr. Ghaffari's presentation highlighted in vitro data demonstrating the potential synergistic effect of combination Amikacin or Clofazimine with high-dose (250ppm) Nitric Oxide (NO) in the treatment of drug resistant mycobacterium abscessus ( M. abscessus ).

All press releases naming this drug 66 releases

Date	Issuer	Release
2026-04-20	Beyond Air Inc.	Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026 beyondair.net ↗
2026-03-17	Beyond Air Inc.	Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial beyondair.net ↗
2026-02-20	Beyond Air Inc.	Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections beyondair.net ↗
2026-02-04	Beyond Air Inc.	Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026 beyondair.net ↗
2025-06-16	Beyond Air Inc.	Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH beyondair.net ↗
2025-04-24	Beyond Air Inc.	Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO) beyondair.net ↗
2025-04-09	Beyond Air Inc.	Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home beyondair.net ↗
2025-01-24	Beyond Air Inc.	Beyond Air® Announces LungFit® PH Receives Market Authorization in Australia beyondair.net ↗
2024-12-03	Beyond Air Inc.	Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy beyondair.net ↗
2024-12-02	Beyond Air Inc.	Beyond Air Receives CE Mark in Europe for the LungFit® PH System beyondair.net ↗
2024-11-11	Beyond Air Inc.	Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting beyondair.net ↗
2024-10-07	Beyond Air Inc.	Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting beyondair.net ↗
2024-07-31	Beyond Air Inc.	Beyond Air® Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia beyondair.net ↗
2024-06-03	Beyond Air Inc.	Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO) beyondair.net ↗
2024-05-01	Beyond Air Inc.	Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting beyondair.net ↗
2023-12-27	Beyond Air Inc.	Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors beyondair.net ↗
2023-11-03	Beyond Air Inc.	Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting beyondair.net ↗
2023-10-17	Beyond Air Inc.	Beyond Cancer™ Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in Mice beyondair.net ↗
2023-10-16	Beyond Air Inc.	Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) in Combination with Checkpoint Inhibitor Therapy During the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics beyondair.net ↗
2023-10-04	Beyond Air Inc.	Beyond Cancer™ Selected to Present Proffered Posters Discussing Data from the UNO Therapy Program at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics beyondair.net ↗
2023-09-27	Beyond Air Inc.	Beyond Cancer™ to Present Initial Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2023 SITC Annual Meeting beyondair.net ↗
2023-09-18	Beyond Air Inc.	Beyond Air® Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder beyondair.net ↗
2023-08-07	Beyond Air Inc.	Beyond Air® Announces Positive Preclinical Data on Role of Nitric Oxide in Autism Spectrum Disorder (ASD) beyondair.net ↗
2023-06-15	Beyond Air Inc.	Beyond Air® Licenses Commercial Rights to Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors for the Treatment of Autism Spectrum Disorder from Hebrew University of Jerusalem beyondair.net ↗
2023-04-19	Beyond Air Inc.	Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the American Association for Cancer Research (AACR) 2023 Annual Meeting beyondair.net ↗
2023-03-14	Beyond Air Inc.	Beyond Cancer™ to Present Two Posters for Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2023 AACR Annual Meeting beyondair.net ↗
2022-12-13	Beyond Air Inc.	Beyond Cancer® Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Method Utilizing Ultra-High Concentration Nitric Oxide (UNO) Induced a Systemic Response that Prevents Metastases beyondair.net ↗
2022-11-10	Beyond Air Inc.	Beyond Cancer™ Presents Promising New In Vivo Data Showing Ultra-High Concentration Nitric Oxide Therapy (UNO) in Combination with Anti-PD-1 During the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting beyondair.net ↗
2022-10-24	Beyond Air Inc.	Beyond Air® Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVID-19 with LungFit® PRO in a Poster Presentation at IDWeek 2022 beyondair.net ↗
2022-10-17	Beyond Air Inc.	Beyond Air® Announces Positive Data from At-Home Pilot Study in Patients with Refractory NTM Lung Infection Treated with (NO) using the LungFit® GO at the CHEST Annual Meeting 2022 beyondair.net ↗
2022-10-05	Beyond Air Inc.	Beyond Cancer™ to Present Pre-Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2022 SITC Annual Meeting beyondair.net ↗
2022-10-03	Beyond Air Inc.	Beyond Air® Announces that Annals of the American Thoracic Society Published a Review of the Third Pilot Study of High Dose Nitric Oxide for Bronchiolitis beyondair.net ↗
2022-08-23	Beyond Air Inc.	Beyond Air® Affiliate Beyond Cancer™ Doses Initial Patient in First-in-Human Phase 1 Study of Ultra-High Concentration Nitric Oxide Therapy at Tel Aviv Sourasky Medical Center (Ichilov) beyondair.net ↗
2022-07-13	Glenmark Pharmaceuticals Ltd. India	Glenmark Pharmaceuticals and SaNOtize Announce Peer Reviewed Publication of Its Phase 3 Clinical Trials on SaNOtize’s Novel Nitric Oxide Nasal Spray for COVID-19 in Lancet Journal glenmarkpharma.com ↗
2022-06-28	Beyond Air Inc.	Beyond Air's LungFit® PH Receives FDA Approval to Treat Term and Near-Term Neonates with Hypoxic Respiratory Failure beyondair.net ↗
2022-05-17	Beyond Air Inc.	Beyond Air® Presents Positive Study Update from the At-Home LungFit® GO Pilot Study for Nontuberculous Mycobacterial Lung Disease at the American Thoracic Society International Conference 2022 beyondair.net ↗
2022-04-25	Beyond Air Inc.	Beyond Air® Reports Positive Long-Term Safety Data for High Concentration Inhaled Nitric Oxide in Bronchiolitis at the Pediatric Academic Societies Meeting 2022 beyondair.net ↗
2022-04-25	Beyond Air Inc.	Beyond Air® Presents Positive Safety and Efficacy Data for Inhaled Nitric Oxide to Treat COVID-19 at ECCMID 2022 beyondair.net ↗
2022-04-11	Beyond Air Inc.	Beyond Cancer™ Announces New Preclinical Data Presented at American Association for Cancer Research (AACR) Showing Ultra-High Concentration Nitric Oxide Therapy Anti-Tumor Effect beyondair.net ↗
2022-03-08	Beyond Air Inc.	Beyond Cancer™ to Present Two Abstracts for Ultra-High Concentration Nitric Oxide Therapy at the 2022 AACR Annual Meeting beyondair.net ↗
2022-02-09	Glenmark Pharmaceuticals Ltd. India	lenmark launches Nitric Oxide Nasal Spray (FabiSpray®) in India for the Treatment of Adult Patients with COVID-19 in partnership with SaNOtize glenmarkpharma.com ↗
2021-11-04	Beyond Air Inc.	Beyond Air® Announces Formation of Beyond Cancer™, a New Private Company Dedicated to Oncology Utilizing Ultra-High Concentration Nitric Oxide to Treat Solid Tumors beyondair.net ↗
2021-10-20	Beyond Air Inc.	Beyond Air® Reports Positive Interim Results for LungFit® GO Pilot Study Using High Concentration Inhaled Nitric Oxide Self-Administered, At-Home for Nontuberculous Mycobacterial Lung Disease beyondair.net ↗
2021-05-13	Beyond Air Inc.	Beyond Air® Presents Data in Hospitalized Patients with Viral Lung Infections (including COVID-19) from LungFit® PRO Programs at ATS 2021 beyondair.net ↗
2021-02-16	Beyond Air Inc.	Beyond Air® Receives Grant for Up to $2.17 million from the Cystic Fibrosis Foundation to Advance the Clinical Development of Inhaled Nitric Oxide to Treat Nontuberculous Mycobacteria Pulmonary Disease beyondair.net ↗
2020-12-07	Beyond Air Inc.	Beyond Air® Initiates Patient Screening for LungFit™ GO Pilot Study for At-Home, Self-Administration of Inhaled Nitric Oxide in Nontuberculous Mycobacteria Lung Disease beyondair.net ↗
2020-11-11	Beyond Air Inc.	Beyond Air® Submits Premarket Approval Application to FDA for LungFit™ PH to Treat Persistent Pulmonary Hypertension of the Newborn beyondair.net ↗
2020-10-21	Beyond Air Inc.	Beyond Air® Approved to Initiate Clinical Study at 150 ppm Nitric Oxide with LungFit™ for the Treatment of Acute Viral Pneumonia Including COVID-19 beyondair.net ↗
2020-10-19	Beyond Air Inc.	Beyond Air® Presents In Vivo Solid Tumor Data Confirming In Situ Cancer Vaccination with a Single Injection of Gaseous Nitric Oxide at the AACR Conference on Tumor Immunology and Immunotherapy beyondair.net ↗
2020-10-19	Beyond Air Inc.	Beyond Air® Presents Pilot Bronchiolitis Data at the CHEST Annual Meeting 2020 beyondair.net ↗
2020-10-19	Beyond Air Inc.	Beyond Air® Presents Data Showing Anti-Coronavirus Activity of Nitric Oxide at the CHEST Annual Meeting 2020 beyondair.net ↗
2020-10-16	Beyond Air Inc.	Beyond Air® Presents Positive New Preclinical Data for the Use of a Single Injection of Gaseous Nitric Oxide as a Novel In situ Cancer Vaccination beyondair.net ↗
2020-09-30	Beyond Air Inc.	Beyond Air® to Present Data on Nitric Oxide in the Treatment of Solid Tumors at the American Association for Cancer Research (AACR) Conference on Tumor Immunology and Immunotherapy beyondair.net ↗
2020-08-27	Beyond Air Inc.	Beyond Air® to Present New Nitric Oxide Data in an e-Poster Presentation at the North America Conference on Lung Cancer 2020 (NACLC 2020) beyondair.net ↗
2020-08-10	Beyond Air Inc.	Beyond Air Publishes New Data on Nitric Oxide to Treat M. Abscessus in the Peer-Reviewed Journal Access Microbiology beyondair.net ↗
2020-06-22	Beyond Air Inc.	Beyond Air Announces Positive Preclinical Data Supporting High Concentration Nitric Oxide as a Potential Treatment for Solid Tumors beyondair.net ↗
2020-06-15	Beyond Air Inc.	Beyond Air Announces Publication of Peer-Reviewed Journal Article in Scientific Reports beyondair.net ↗
2020-06-15	Beyond Air Inc.	Beyond Air Announces First Patient Enrolled in its U.S. Study of Nitric Oxide Therapy Using the LungFit™ System in COVID-19 Patients beyondair.net ↗
2020-05-26	Beyond Air Inc.	Beyond Air Receives Approval from Health Canada to Study Nitric Oxide Generated and Delivered by the LungFit™ in COVID-19 Patients beyondair.net ↗
2020-05-20	Beyond Air Inc.	Beyond Air Achieves Primary Endpoint in Pilot Bronchiolitis Study beyondair.net ↗
2020-05-15	Beyond Air Inc.	Beyond Air™ to Present New Data in an e-Poster Presentation at the Upcoming AACR Virtual Annual Meeting II on June 22nd to 24th beyondair.net ↗
2020-04-16	Beyond Air Inc.	Beyond Air to Initiate Clinical Study Evaluating High Concentration Nitric Oxide for the Treatment of COVID-19 Patients in the United States beyondair.net ↗
2020-03-16	Beyond Air Inc.	Beyond Air Submits Investigational Device Exemption (IDE) to the United States Food and Drug Administration (FDA) for the Treatment of COVID-19 Patients beyondair.net ↗
2019-11-25	Beyond Air Inc.	Beyond Air Signs Agreement with MESA Specialty Gases & Equipment for Nitric Oxide and Nitrogen Dioxide Calibration Gas Supply beyondair.net ↗
2019-10-16	Beyond Air Inc.	Beyond Air™ Provides Update on High Concentration Nitric Oxide (NO) Animal Studies Using LungFit™ beyondair.net ↗
2019-10-01	Beyond Air Inc.	Beyond Air™ Presents Data at the 2019 European Respiratory Society (ERS) International Congress in Madrid, Spain beyondair.net ↗

Evidence & citations 18 cited values

Every value below carries the sentence it was read from. 162 sources stand behind the page.

Field	Value	Cited text
Known as	nitric oxide	“Inhaled nitric oxide (iNO) has been shown to result in benefits in moderate to vigorous physical activity (MVPA) in patients with fibrotic interstitial lung disease (f-ILD)...” PMID 39141673 ↗ Dec 2024 149 “Inhaled nitric oxide will be administered via the anesthesia machine, under the supervision of the attending Anesthesiologist, at a concentration of 20 parts per million (ppm)...” NCT07125443 ↗ “Inhaled nitric oxide (iNO) is commonly administered for selectively inhaled pulmonary vasodilation and prevention of oxidative injury after lung transplant (LT).” PMID 34787647 ↗ Jan 2022 “Pulsed, Inhaled Nitric Oxide (iNO) for the Treatment of Patients With Serious Disease or Conditions Associated With Pulmonary Hypertension” NCT05356052 ↗ “A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis” NCT05747508 ↗ “such as nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H₂S), are small gaseous signaling molecules” NCT06739538 ↗ “Subjects will be treated with nitric oxide by means of an INOpulse DS-C device using an INOpulse nasal cannula.” NCT01728220 ↗ “Traditional treatment plus inhaled nitric oxide therapy (20-40 ppm, continuous administration for 12-24 hours)” NCT07639931 ↗ “before and after exposure to inhaled nitric oxide in patients with pulmonary arterial hypertension (PAH)” NCT02220023 ↗ “supplemental Nitric Oxide (NO) gas delivered during cardiac surgery” NCT03946462 ↗ “Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo” NCT04421508 ↗ Show 139 more sources
Known as	Enovid	“Nitric Oxide Nasal Spray "Enovid"” NCT05012319 ↗
Known as	gNO	“gases Nitric Oxide (gNO)” NCT04259684 ↗
Known as	Inhaled nitric oxide	“Inhaled nitric oxide is a controversial treatment for premature infants with severe respiratory failure.” PMID 16000352 ↗ Jul 2005
Known as	inhaled nitric oxide, iNO, iNOMax	“inhaled nitric oxide, iNO, iNOMax” NCT03079102 ↗
Known as	Inhaled NO	“Inhaled NO has regulatory approval in man by the Food and Drug Administration (FDA) and by the European Medicines Agency (EMA) for the treatment of several pulmonary pathologies.” NCT04988932 ↗ 1 “Inhaled Nitric Oxide Intervention: Inhaled NO is a selective pulmonary vasodilator and has been shown to improve blood flow to well-ventilated lung areas” NCT04231760 ↗
Known as	iNO	“Respiratory failure in term newborns is associated with increased rates of death and long-term neurodevelopmental problems. This large international multicenter trial...” NCT00005776 ↗ 32 “Research study evaluating the individual and combined effects of inhaled nitric oxide (iNO) and inhaled prostacyclin (iPGI2), on the function of the right heart after surgery...” NCT01717209 ↗ “The goal of this clinical trial is to learn the formation and recovery rate of methemoglobin (MetHb) in severely sick patients with pneumonia who receive high doses of inhaled...” NCT06950294 ↗ “Inhaled nitric oxide (iNO), which is known mainly from the pulmonary hypertension literature for its therapeutic role in pulmonary arterial hypertension, has been proposed as a...” NCT04996667 ↗ “Inhaled nitric oxide (iNO) has been shown to result in benefits in moderate to vigorous physical activity (MVPA) in patients with fibrotic interstitial lung disease (f-ILD)...” PMID 39141673 ↗ Dec 2024 “One such therapy is inhaled nitric oxide (iNO), which is a selective pulmonary vasodilator that has been shown to reduce total pulmonary resistance and improve systemic venous...” NCT01607983 ↗ “AIMS: Inhalation of nitric oxide (iNO) during myocardial ischaemia and after reperfusion confers cardioprotection in preclinical studies via enhanced cyclic guanosine...” PMID 29800130 ↗ Aug 2018 “BACKGROUND: While inhaled nitric oxide (iNO) has revealed benefit in cardiac arrest in an animal model, no published data has yet demonstrated the impact of iNO in humans with...” PMID 34229057 ↗ Jul 2021 “Adult patients undergoing liver transplantation with prospective intervention involving intraoperative administration of inhaled nitric oxide (iNO) and prospective data collection.” NCT07125443 ↗ “Study to determine if inhaled nitric oxide (iNO) given through a special delivery device (INOpulse® DS) is safe and efficacious in treating Pulmonary Arterial Hypertension (PAH).” NCT01457781 ↗ “Inhaled nitric oxide (iNO) has been studied as an adjunct treatment to avoid the use of high positive end-expiratory pressure and inspired oxygen in treatment-refractory hypoxia.” PMID 38325012 ↗ Feb 2024 Show 22 more sources
Known as	INO max	“INO max®” NCT00551642 ↗
Known as	INOmax (nitric oxide) for inhalation	“INOmax (nitric oxide) for inhalation” NCT01388842 ↗
Known as	Nitric Oxide Gas	“Drug: Nitric Oxide Gas” NCT04306393 ↗
Known as	NO	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06261827 ↗
Known as	NO, nitrogen monoxide	“NO, nitrogen monoxide” NCT01255215 ↗
Known as	NONI	“This is a double-blinded, placebo-controlled parallel, phase II clinical efficacy study evaluating Nitric Oxide Nasal Irrigation (NONI) for the treatment of COVID-19 in...” NCT04443868 ↗
Known as	NONS	“A Double-Blinded, Placebo-Controlled Parallel, Phase 3 Clinical Efficacy Study Evaluating Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in...” NCT05012319 ↗ 1 “Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in Individuals With Mild COVID-19” NCT05599919 ↗
Action	Activate	“NO has been shown to activate CFTR” NCT00570349 ↗
Modality	Other / unclassified	“nitric oxide gas” NCT00545298 ↗
Route	Inhaled	“is given through a cushioned mask placed over the mouth and nose.” NCT00001303 ↗
Target	CFTR	“NO has been shown to activate CFTR” NCT00570349 ↗